Non-Small-Cell Lung Cancer

Study Shows Taxotere Well Tolerated and Effective

Published in Cancer Weekly, February 15th, 2000

Monotherapy with the chemotherapeutic agent docetaxel (Taxotere) represents an effective and safe first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC), according to the final results presented at the 10th International Congress on Anti-Cancer Treatment (ICACT), held in Paris, France.

The data, from a Phase III trial, showed docetaxel to be well tolerated among patients with metastatic or unresectable localized NSCLC who were randomized to single-agent therapy with docetaxel. Patients treated with docetaxel, a taxane, also had a significantly better survival at 20 months than patients who were assigned to receive best supportive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-02-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry